Mangoceuticals, Inc. (MGRX)

Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc.

Novo Nordisk and Eli Lilly do not have a weight-loss drug partnership with telehealth website Mangoceuticals Inc , spokespeople for both companies said, rejecting a press release issued by the company on Thursday that described arrangements with the two leading drugmakers.

Telehealth company Mangoceuticals said on Thursday it has partnered with Eli Lilly and Novo Nordisk to sell the drugmakers' blockbuster weight-loss drugs through its platform.

Dallas, TX, May 27, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions, is excited to share groundbreaking results from field studies based on its patented antiviral compound which it refers to as “MGX-0024”. The field studies were conducted by Solice International at Duraiswamy Farm in Palladam, Tamil Nadu, India. These studies, targeting respiratory diseases in chickens, like Newcastle Disease and Chronic Respiratory Disease (CRD), showed MGX-0024, delivered through drinking water, achieved 100% survival against respiratory illnesses in a large-scale trial, offering a promising solution for poultry health and avian flu defense.

New York, New York, Dallas, Texas, and Toronto, Ontario--(Newsfile Corp. - April 28, 2025) - ArcStone Securities and Investments Corp. ("ArcStone"), a leading cross-border financial services firm, today announced the publication of an industry report on the rapidly emerging oral stimulant pouch market — a multi-billion dollar, high-growth vertical within the health and wellness consumer sector. In the report, ArcStone highlights Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals") following two transformative transactions: Acquisition of the North American rights to Diabetinol, expanding its health and wellness product pipeline; and Acquisition of selective executives, IP, and assets of Smokeless Technology Corp., establishing a leadership position in the oral stimulant pouch market Mangoceuticals, Inc. is strategically positioned to capitalize on this expansion by leveraging its proprietary science, IP portfolio, and product rights to target large addressable markets including energy, mood enhancement, weight loss, diabetes management, and more.

Transaction Marks ArcStone's Continued Cross-Border M&A Franchise Involving a NASDAQ-Listed Company, Underscoring the Strength of Its Global Platform and Financial Acumen In the news release, "ArcStone Securities and Investments Corp. serves as exclusive financial advisor to Mangoceuticals Inc." issued on 25-Apr-2025 by ArcStone over Newsfile, the company has advised that the main heading should not have included "acquisition of Smokeless Technology Corp." The complete, corrected release follows: Transaction Adds Executive Bench Strength, IP and Launches New Business Vertical for Mangoceuticals in Lucrative Oral Stimulant Pouch Segment on the Heels of the Significant Success of Turning Point Brands and Philip Morris International New York, New York and Dallas, Texas--(Newsfile Corp. - April 26, 2025) - ArcStone Securities and Investments Corp. ("ArcStone"), a cross-border financial services firm, is pleased to announce its role as exclusive financial advisor to Mangoceuticals Inc. (NASDAQ: MGRX) ("Mangoceuticals") in its acquisition of IP, assets and technology from Smokeless Technology Corp. ("Smokeless Tech"), a Canadian-based innovator and disruptor in stimulant-based pouches and functional wellness delivery systems. This transaction marks ArcStone's strategic M&A advisory expertise advising a NASDAQ-listed acquirer and a privately held international company, underscoring the strength of its cross-border platform and domain expertise in health and wellness categories.

Transaction Marks ArcStone's Continued Cross-Border M&A Franchise Involving a NASDAQ-Listed Company, Underscoring the Strength of Its Global Platform and Financial Acumen Transaction Adds Executive Bench Strength, IP and Launches New Business Vertical for Mangoceuticals in Lucrative Oral Stimulant Pouch Segment on the Heels of the Significant Success of Turning Point Brands and Philip Morris International New York, New York, Dallas, Texas and Toronto, Ontario--(Newsfile Corp. - April 25, 2025) - ArcStone Securities and Investments Corp. ("ArcStone"), a cross-border financial services firm, is pleased to announce its role as exclusive financial advisor to Mangoceuticals Inc. (NASDAQ: MGRX) ("Mangoceuticals") in its acquisition of IP, assets and technology from Smokeless Technology Corp. ("Smokeless Tech"), a Canadian-based innovator and disruptor in stimulant-based pouches and functional wellness delivery systems. This transaction marks ArcStone's strategic M&A advisory expertise advising a NASDAQ-listed acquirer and a privately held international company, underscoring the strength of its cross-border platform and domain expertise in health and wellness categories.

DALLAS, TX, April 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals Inc. (NASDAQ: MGRX) (“Mangoceuticals” or “MGRX”), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, is pleased to announce that it has entered into an Intellectual Property Purchase Agreement to acquire all intellectual property, product formulations, know-how, distribution, supplier relationships and related assets of Smokeless Technology Corp. (“Smokeless Tech”), a Canadian-based pouch innovation company specializing in stimulant and functional pouches.

DALLAS, TX / ACCESS Newswire / April 22, 2025 / Mangoceuticals Inc. (NASDAQ:MGRX) is on a mission to rewrite the playbook for men's performance, health, and vitality. Its pursuit comes at a time when opportunities have become enormous, with patent expirations on several of the world's most popular health and wellness drugs, opening vast pathways to exploit segmented market opportunities, each worth billions.

Dallas, TX & Quebec, Canada, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of men's wellness products and services via a secure telemedicine platform, is pleased to announce that it has entered into an exclusive Master Distribution Agreement with Propre Energie, Inc., the developer of skincare brand Dermytol®, a clinically proven treatment designed to improve skin tone and reduce hyperpigmentation.

Dallas, TX, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, today announced the acquisition of patent number WO 2023/086647 PCT/US2022/049857, for mushroom-derived compositions and methods of treatment. This new addition to MangoRx's intellectual property portfolio highlights the Company's commitment to innovative solutions that support holistic health and wellness.

Dallas, Texas, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform learned earlier this morning that Eli Lilly has made certain public claims alleging, and has stated that it has filed a lawsuit against MangoRx claiming, that MangoRx improperly copied its weight-loss medicine, Zepbound and Mounjaro. MangoRx strongly refutes any and all claims made by Eli Lilly regarding the sale of compounded tirzepatide. MangoRx believes it has strong arguments against Eli Lilly's claims and intends to vigorously defend itself in this matter.

Dallas, Texas--(Newsfile Corp. - October 18, 2024) - Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform,, is pleased to announce it will be presenting at the Centurion One Capital 2nd Annual Bahamas Summit, which will be taking place at the exclusive Rosewood Baha Mar Hotel from Tuesday, October 22nd to Wednesday, October 23rd, 2024, in Nassau, Bahamas. Jacob Cohen, Founder and CEO, is scheduled to present on Wednesday, October 23rd at 11:10 EDT.

DALLAS, TX, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-15 (the “Reverse Stock Split”). The Reverse Stock Split will become effective on October 16, 2024 at 12:01 a.m. Eastern Time (the “Effective Time”), with shares expected to begin trading on the Nasdaq Capital Market, on a split-adjusted basis, at market open on October 16, 2024. In connection with the Reverse Stock Split, every fifteen shares of the Company's common stock issued and outstanding as of the Effective Time will be automatically converted into one share of the Company's common stock. No change will be made to the trading symbol for the Company's shares of common stock, “MGRX”, in connection with the reverse split.

Dallas, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, announces the release of its latest innovation, “TRIM,” a compounded, oral dissolvable Tirzepatide tablet. Available for purchase at $399 per month, this new product offers patients an advanced and convenient alternative to injectable therapies.

MangoRx aims to capitalize on growing demand for GLP-1 treatments to drive revenue growth and expand market share in the weight loss category